HCPCS code J2327: Injection, risankizumab-rzaa, intravenous, 1 mg

Key Takeaways

HCPCS code J2327 identifies Injection, risankizumab-rzaa (Skyrizi), intravenous, 1 mg – established by CMS effective January 1, 2023.

Bill 600 units for Crohn’s disease IV infusion and 1,200 units for ulcerative colitis – each Skyrizi single-dose vial is 600 mg, and 1 mg equals 1 HCPCS unit.

J2327 requires JW or JZ modifier documentation for all Medicare and many Medicaid claims – J3590 applies to the subcutaneous formulation only.

Practice management software like Pabau helps infusion and dermatology practices track modifier requirements, NDC crosswalks, and prior authorization status for biologics like J2327.

HCPCS code J2327 is the billing code for injection, risankizumab-rzaa, intravenous, 1 mg. CMS established the code effective January 1, 2023 for the intravenous formulation of this IL-23 inhibitor biologic, marketed as Skyrizi and used for Crohn’s disease and ulcerative colitis induction therapy.

This reference covers the code description, approved indications, dosing unit calculations by indication, ICD-10 crosswalk, modifier requirements, reimbursement, and common denial patterns for HCPCS code J2327. Practices using claims management software that handles biologics billing can catch unit and modifier errors before submission.

HCPCS code J2327: Description and code properties

HCPCS code J2327 carries the official description: Injection, risankizumab-rzaa, intravenous, 1 mg. CMS placed this code under the “Drugs Administered Other than Oral Method” category (J0013-J8999), specifically within the “Drugs, Administered by Injection” subcategory (J0013-J7175).

The code is maintained by CMS through the HCPCS Level II system and is valid for dates of service on or after January 1, 2023.

One SERP result (coding.health) incorrectly identifies J2327 as dupilumab. That is a factual error. J2327 is exclusively risankizumab-rzaa (Skyrizi, manufactured by AbbVie). Dupilumab (Dupixent) has its own separate HCPCS code and must never be billed under J2327.

Approved indications for J2327

The FDA has approved risankizumab-rzaa for several inflammatory conditions. For IV infusion billing under HCPCS code J2327, the intravenous route applies specifically to Crohn’s disease and ulcerative colitis induction therapy. Subcutaneous administration (plaque psoriasis, psoriatic arthritis, and maintenance dosing for IBD) is billed under HCPCS code J3590, not J2327.

Confirming the correct route before submitting a claim matters more with biologics than almost any other drug category. Payers routinely auto-deny J2327 claims when the diagnosis code suggests a condition for which only the subcutaneous route is approved, or when documentation does not specify IV administration.

Practices that track practice compliance workflows for biologics catch these route-related mismatches before submission.

• Crohn’s disease (CD) induction: IV infusion covered under J2327, 600 mg per infusion
• Ulcerative colitis (UC) induction: IV infusion covered under J2327, 1,200 mg per infusion
• Plaque psoriasis: Subcutaneous only, billed under J3590
• Psoriatic arthritis: Subcutaneous only, billed under J3590

How to calculate J2327 billing units

This is where most billing errors occur. Each Skyrizi single-dose vial contains 600 mg. Because HCPCS code J2327 is priced per 1 mg, the billing unit count equals the dose in milligrams. According to the Skyrizi billing guide, 1 mg equals 1 HCPCS unit.

Billing 600 units for a UC patient (instead of 1,200) results in a claim for half the drug cost. Billing 1,200 for a CD patient triggers a medical necessity denial. Verify the indication against the prescribing physician’s order before calculating units.

NDC crosswalk requirement

Most payers require the National Drug Code (NDC) alongside HCPCS code J2327. The NDC identifies the exact drug product and lot. Enter the 11-digit NDC in the appropriate claim field (Box 24A on a CMS-1500 or the equivalent electronic field), followed by the NDC unit qualifier and quantity.

Failure to include a valid NDC is a common reason for claim rejection under Medicare Part B and many commercial contracts. For HIPAA-compliant billing documentation, your practice management system should store the administered NDC at the point of service, not at billing time.

ICD-10 codes that support medical necessity for J2327

Every J2327 claim must be paired with an ICD-10-CM diagnosis code that supports medical necessity for intravenous risankizumab-rzaa. Payer-specific LCD policies define the covered diagnosis list, so verify against the relevant Medicare Administrative Contractor (MAC) or commercial plan policy before submitting.

The following codes are among those recognized under BCBS Florida’s MCG policy 09-J3000-45 for J2327 IV infusion. Other payers may differ.

Always confirm the covered ICD-10 list against the payer’s current LCD or coverage policy. Many commercial payers also require documentation of prior biologic therapy failure (step therapy) before approving risankizumab-rzaa. Specialty practices managing complex drug billing across multiple specialties, such as IVF CPT codes, benefit from linking diagnosis codes directly to drug order workflows in their practice management system.

Modifiers required for J2327

CMS explicitly lists J2327 in its JW and JZ modifier policy document. These modifiers became mandatory for Medicare Part B drug claims and are increasingly required by Medicaid programs and commercial payers as well. Using the correct modifier is not optional: a claim submitted without either JW or JZ on a J2327 line may be rejected or recouped.

JW modifier: Drug wastage

The JW modifier identifies unused drug from a single-dose vial that was discarded. For J2327, this applies when a portion of the vial was administered and the remainder could not be used. You bill two separate line items: one for the administered dose (without JW) and one for the wasted amount (with JW).

Documentation in the medical record must state the amount administered and the amount discarded. The paperless documentation approach makes capturing this in real time far easier than a paper-based nursing record.

JZ modifier: No drug wastage

The JZ modifier confirms that no drug was wasted. Bill it on the J2327 line when the entire vial contents were administered. For CD patients receiving 600 mg from a 600 mg vial, the full vial is used and JZ applies.

For UC patients receiving 1,200 mg across two vials, both vials are fully used and JZ applies to each line. Using digital intake forms linked to your drug administration record helps ensure JW/JZ documentation is captured at the point of care.

Manage biologics billing without the manual headaches

Pabau's claims management tools help infusion and specialty practices track modifier requirements, prior authorization status, and NDC documentation for high-cost drug claims like J2327.

Book a demo

Reimbursement and fee schedule for J2327

Medicare Part B reimburses most separately payable biologics at ASP (Average Sales Price) plus 6% when administered in a physician office or hospital outpatient department. For infusion suite and other settings, payment rules vary.

CMS updates ASP quarterly, so the reimbursement rate for HCPCS code J2327 changes four times per year. Always verify current rates against the CMS fee schedule lookup for the applicable quarter before estimating reimbursement.

Commercial payers reimburse J2327 at rates ranging from ASP-based formulae to contracted WAC (Wholesale Acquisition Cost) or AWP (Average Wholesale Price) percentages. Some payers carve out specialty biologics to a specialty pharmacy, bypassing the buy-and-bill model entirely.

Buy-and-bill vs specialty pharmacy

In the buy-and-bill model, the provider purchases Skyrizi directly, administers it, and bills J2327 to the payer for reimbursement. In the specialty pharmacy model, the payer directs the prescription to a contracted pharmacy, the drug ships to the practice, and the provider bills only the administration CPT code 96365.

Other high-cost biologics billed through the buy-and-bill model, such as natalizumab under HCPCS code J2323, follow similar reimbursement and channel-eligibility logic.

Whether buy-and-bill is available for a specific patient depends on the payer contract, the site of service, and whether the payer has a specialty pharmacy carve-out. Practices billing for skin clinic software including biologics need to verify channel eligibility for each payer separately.

Place of service considerations

Place of service (POS) code affects reimbursement rates under Medicare. J2327 infusion is typically administered in one of these settings:

• POS 11 (Physician Office): Higher reimbursement under the non-facility RVU schedule, and the provider must have infusion capability on-site
• POS 22 (Hospital Outpatient): Lower physician payment, with the hospital billing the facility component under APC
• POS 19 (Off-Campus Outpatient Hospital): Follows site-neutral payment rules where applicable

Infusion suites billing other high-cost intravenous drugs, such as chemotherapy under CPT code 96413, apply the same POS-based reimbursement logic.

Practices that also administer HCPCS code S9379 for home infusion therapy should confirm site-of-service rules separately, since home infusion follows its own payment structure.

Prior authorization and payer coverage for J2327

Prior authorization (PA) is almost universally required for J2327 across Medicare Advantage, Medicaid managed care, and commercial plans. Medicare fee-for-service does not require PA for most physician-administered drugs, but Medicare Advantage plans may impose their own PA requirements. Confirm with the specific plan before administering the first infusion.

Most payers applying PA criteria for risankizumab-rzaa IV infusion require:

• Confirmed diagnosis (Crohn’s disease K50.xx or ulcerative colitis K51.xx) via endoscopy or imaging
• Documentation of moderate-to-severe disease activity (CDAI, Mayo score, or equivalent)
• Failure of at least one conventional therapy (corticosteroids, immunomodulators) and typically one TNF inhibitor
• Prescribing physician attestation of IV route necessity
• Planned infusion site documentation

Step therapy requirements mean the PA for J2327 IV induction is often separate from any existing PA the patient holds for subcutaneous Skyrizi maintenance. Managing this correctly requires patient compliance tracking across the induction and maintenance phases.

Noridian Medicare, as an example MAC, posts modifier and HCPCS changes on their provider portal, including updates to J2327 effective for dates of service on and after January 1, 2023.

Common billing errors and denial patterns for J2327

Biologics generate a disproportionate share of claim denials relative to their volume, because the dollar values are high, the documentation requirements are complex, and the margin for error is small. For J2327, the most frequent denial triggers follow predictable patterns.

• Wrong unit count: Billing 600 units for a UC patient or 1,200 units for a CD patient. Verify indication against the prescribing order every time.
• Missing JW or JZ modifier: CMS and many payers reject J2327 lines without one of these modifiers. Neither is optional.
• Using J2327 for the subcutaneous formulation: SC risankizumab-rzaa is J3590. J2327 is IV only. Route mismatch = automatic denial.
• Omitting the NDC: Many payers require a valid 11-digit NDC on the claim. Missing NDC = rejection at the clearinghouse level.
• Expired or incorrect prior authorization: A PA for SC Skyrizi does not cover IV Skyrizi under most payer policies. Obtain a separate PA for the IV formulation.
• ICD-10 mismatch with route: Billing J2327 with a psoriasis diagnosis (L40.0) signals an IV infusion for an indication where only SC is approved. Payers will deny.
• Miscoding as dupilumab: Some billers, misled by incorrect coding references, have used J2327 for dupilumab (Dupixent). These are different drugs with different codes. Always verify the drug name against the HCPCS descriptor.

Billing workflows that link the administered drug record directly to the claim line reduce these errors significantly, giving specialty practices an integrated documentation pathway for drug administration claims.

Using prescription management tools that record the specific biologic administered, the route, the dose, and the vial NDC at the point of care gives your billing team exactly what they need to submit correctly the first time.

Documentation requirements for J2327 claims

Adequate documentation is the foundation of a defensible J2327 claim. For Medicare and most commercial payers, the medical record must support both the medical necessity of risankizumab-rzaa and the specifics of the infusion encounter.

• Diagnosis documentation: Active Crohn’s disease or ulcerative colitis confirmed by clinical assessment, endoscopy, or imaging within the required timeframe
• Drug order: Prescribing physician’s order specifying risankizumab-rzaa, route (IV), dose (600 mg for CD, 1,200 mg for UC), and infusion schedule
• Administration record: Nursing record showing date, time, drug name, lot number, NDC, dose administered, infusion duration, and any adverse events
• Wastage documentation: If JW modifier is used, the record must state the amount administered and the amount wasted with the reason
• Prior therapy failure: Chart notes or referral letters documenting failure of required prior therapies (for PA purposes and audit defense)
• Prior authorization number: PA number and expiration date must be on file and available for payer audit

Practices implementing HIPAA-compliant documentation workflows for infusion services should build the documentation checklist above into their infusion nursing protocol. Retrospective documentation is both harder to substantiate and a known audit risk for high-cost biologics.

For dermatology practices managing psoriasis and IBD-related biologics via dermatology EMR software, having the administration record, diagnosis confirmation, and PA number linked in the same patient record simplifies audit responses considerably. Practice management platforms that integrate infusion documentation with claims submission keep the clinical record and the billing department in sync.

Conclusion

HCPCS code J2327 is a high-stakes code. With a single infusion worth hundreds of units at ASP rates, the financial impact of a denied or underpaid claim is significant. The most common failure points are unit miscalculation by indication, missing JW/JZ modifiers, and route-diagnosis mismatches.

Pabau’s practice management tools give specialty and infusion practices a structured way to connect the drug administration record to the billing workflow, capturing the NDC, modifier selection, and diagnosis code linkage at the point of care.

For practices managing high-cost biologics like J2327, that connection is the difference between a clean first-pass claim and a denial cycle that takes weeks to resolve. To see how Pabau handles biologics billing workflows, book a demo.

Billing teams managing multiple specialty and DME codes alongside J2327 may also want to review CCSD code 0636G, HCPCS code E0483, and HCPCS code A4613 for related billing scenarios.

Continue your research

Need a structured approach to claims accuracy? Pabau claims management software walks through how to connect drug administration records directly to claim submission for specialty biologics.

Managing infusion therapy documentation? IV therapy EMR software covers the documentation and workflow requirements for infusion practice operations.

Looking for compliance guidance for specialty practices? HIPAA compliance guide outlines the documentation standards applicable to infusion and specialty drug administration.

Frequently asked questions